NATIONAL CENTER FOR HIV, VIRAL HEPATITIS, STD, AND TB PREVENTION

Lifetime Productivity Loss Due to HIV Mortality in the United States

Md Hafizul Islam, PhD, MBA; Harrell Chesson, PhD; Angela Hutchinson, MPH, PhD; Ram K. Shrestha, PhD; Ruiguang Song, PhD; Alex Viguerie, PhD; Paul G. Farnham, PhD Centers for Disease Control and Prevention, Atlanta, GA, USA

BACKGROUND

- HIV related mortality has declined over time, improving the life expectancy among people with HIV (PWH).
- Our goal is to update the estimates of the lifetime productivity loss per HIV infection to help quantify the economic burden of HIV and inform cost-effectiveness analyses.

METHODS

- We developed a method based on the human capital approach to estimate mortality related lifetime productivity loss (LPL) per HIV infection in the United States.
- We incorporated published data on
 - \circ Average annual productivity (P)
 - ✓ Market and nonmarket productivity
 - Remaining life expectancy at HIV diagnosis (E)
 - \circ Number of life years lost (L) due to premature death among PWH
 - Number of years from HIV infection to diagnosis (M)
 - Percentage of deaths in PWH attributable to HIV (Z)
- Base case used 2018 population-based life expectancy data at the median age of HIV diagnosis among all PWH in the US.
- We also examined other life expectancy data sources:
 - Data from all PWH in 2010
 - Data from cohorts on antiretroviral therapy (ART)
- We used 2022 USD and 3% annual discount rate (r) in calculation of discounted LPL.




Figure 1: A schematic of the calculation and year by year representation of the lifetime discounted productivity and productivity loss

RESULTS

		Productivity loss per HIV infection*		
Scenario		All	Male	Female
PWH 2018 vs 2010	PWH in 2018 (Base case)	\$84,000	\$82,900	\$85,200
	PWH in 2010	\$126,300	\$121,400	\$130,700
Current vs Early ART	Cohorts on ART (ART initiated 2015-2019)	\$18,200	\$13,900	\$21,000
	Cohorts on ART (ART initiated 1996-2014)	\$37,100	\$33,900	\$40,000
*Rounded to the nearest 100 and reported in 2022 USD				

METHODS (CONTINUED)



$$(\beta + \beta^2 + \dots + \beta^L) \times Z \times \beta^E \times \beta^M$$

where $\beta = \frac{1}{1+r}$

Productivity loss per HIV infection*

CONCLUSIONS

- Our study provides a useful update of the estimated lifetime productivity loss per HIV infection associated with HIV mortality.
- We estimated a 33% reduction in the lifetime discounted productivity loss per HIV infection due to HIV mortality over the past decade, comparing 2018 vs 2010 estimates.
- Modern ART treatment, including immediate ART initiation, has contributed to declines in HIV-mortality related productivity losses.

LIMITATIONS

- We used population averages to estimate productivity losses for persons with HIV in general, thus they are not specific to age, disease stage at diagnosis or transmission group.
- Our study was limited to mortality-related productivity loss of HIV and did not include productivity loss of HIV morbidity.

REFERENCES

- Grosse SD, et al. Estimated annual and lifetime labor productivity in the United States, 2016: implications for economic evaluations. J Med Econ. Jun 2019;22(6):501-508.
- Siddiqi AE, et al. Life Expectancy after HIV Diagnosis 2008-2018, United States [Abstract 761]. Presented at: Conference on Retroviruses and Opportunistic Infections; February 12-16, 2022; Virtual.
- Trickey A, et al. Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies. Lancet HIV. May 2023;10(5):e295-e307.

CONTACT INFO Md Hafizul Islam qla0@cdc.gov

